A Vascular physician’s View of Venous Thromboembolism and Apixaban

Click to increase image sizeClick to decrease image size

Disclaimer

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Future Medicine Ltd.

Financial & competing interests disclosure

A Cohen reports receiving consulting fees from Bayer, Boheringer-Ingelheim, BMS, Daiichi, GSK, Johnson & Johnson, Mitsubishi Pharma, Pfizer, Portola, Sanofi, Schering Plough, Takeda, and XO1. He has advisory board membership with Bayer, BMS, Daiichi, Johnson & Johnson, Pfizer, Portola, Sanofi, and XO1. He has received payments for lectures including speakers bureau services, payments for preparation of reports and payment for development of educational presentations from, Bayer, Boheringer-Ingelheim, BMS, Daiichi, GSK, Johnson & Johnson, Mitsubishi Pharma, Pfizer, Portola, Sanofi, and Schering Plough. He is an advisor to the UK Government Health Select Committee, the all-party working group on thrombosis, the Department of Health, and the NHS on the prevention of VTE. He is also an advisor to Lifeblood: the thrombosis charity and is the founder of the European educational charity the Coalition to Prevent Venous Thromboembolism. A Cohen has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Notes on contributors

Alexander Cohen

Alexander Cohen speaks to Wing Han Wu, Commissioning Editor: Dr Cohen is a vascular physician and epidemiologist involved in clinical work, designing, managing and analyzing clinical trials from Phase I to IV. He is the Chairman and member of many international steering committees for multicenter trials, and epidemiological and pharmaco-economic studies. Dr Cohen graduated with honors in Medicine and Surgery from the University of Melbourne, Australia (MBBS). He achieved his fellow of the Royal Australasian College of Physicians (FRACP) in 1990, and received an MSc in Epidemiology in 1991 from the University of London. His MSc thesis in 1991 was on the Metabolic Syndrome in South Asia. In 1998, he achieved MD with a thesis on Epidemiology of VTE and Thromboprophylaxis. He has written or co-authored over 300 publications since 1990, including 40 publications in The Lancet and New England Journal of Medicine.